Company Filing History:
2 out of 321 
2 out of 4 Years Active: 2014-2015
Title: Innovations of Inventor Sun-Ha Yoon in Autoimmune Disease Treatment
Introduction
Sun-Ha Yoon, an accomplished inventor based in Daejeon, South Korea, has made significant contributions to the field of biotechnology, particularly in the treatment of autoimmune diseases. With two patents to his name, Yoon's inventions showcase his dedication to advancing medical science and improving patient outcomes.
Latest Patents
Yoon's latest patents include innovative solutions for treating autoimmune diseases through dual antagonists. The first patent involves a dual antagonist for TNF-α and IL-21, presenting a TNFR2-IL21R fusion protein that acts as a powerful double-antagonist. This composition effectively reduces inflammation and enhances anti-inflammatory responses, particularly for conditions like rheumatoid arthritis. The second patent features a TNFR2-TWEAKR fusion protein, which serves as a dual antagonist to TNF-α and TWEAK. This invention has demonstrated remarkable efficacy in reducing inflammatory cytokine secretion and promoting immune regulation through Treg cells, marking a significant step forward in therapeutic strategies for autoimmune diseases.
Career Highlights
Throughout his career, Sun-Ha Yoon has been affiliated with notable institutions such as the Korea Research Institute of Bioscience and Biotechnology and the Industry-Academic Cooperation Foundation of the Catholic University of Korea. His work in these organizations has positioned him at the forefront of research aimed at understanding and combating autoimmune disorders.
Collaborations
Yoon has collaborated with esteemed colleagues, including Young Woo Park and Ki Won Jo, contributing to the dynamic research environment that fosters innovation in biotechnology. Such collaborations have been instrumental in the development of his patented technologies, enabling shared insights and expertise.
Conclusion
Sun-Ha Yoon’s pioneering inventions are vital contributions to the field of autoimmune disease treatment. His dual antagonist fusion proteins represent a breakthrough in therapeutic approaches, showcasing the potential for improved patient care. As advancements in biotechnology continue to evolve, Yoon's work serves as an inspiring example of how innovation can lead to meaningful changes in healthcare.